trending Market Intelligence /marketintelligence/en/news-insights/trending/UI1hM2kdfglKDkHfQN_4LQ2 content esgSubNav
In This List

Aerie Pharmaceuticals' glaucoma drug wins FDA panel backing

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Aerie Pharmaceuticals' glaucoma drug wins FDA panel backing

A U.S. Food and Drug Administration advisory panel recommended the approval of Aerie Pharmaceuticals Inc.'s experimental glaucoma drug Rhopressa.

The panel voted 9-1 in favor of Rhopressa, concluding that its benefits outweigh its risks.

In addition, the panel voted unanimously in favor of the treatment being effective in lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Glaucoma is a condition that damages the optic nerve.

The regulator is expected to decide on the drug's approval Feb. 28, 2018. It is not required to act on the advice of its advisory panels, but generally does so.